跳至主要内容
临床试验/EUCTR2013-003932-56-GB
EUCTR2013-003932-56-GB进行中(未招募)不适用

ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. - ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F Am 01

niversity of Liverpool0 个研究点目标入组 100 人开始时间: 2014年3月31日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Borderline resectable mass in the pancreatic head as defined by CT criteria.
  • 2. Histologically or cytologically proven pancreatic ductal adenocarcinoma (including variants).
  • 3. Able to undergo biliary drainage using a fully covered self expanding metal stent.
  • 4. Age = 18 years.
  • 5. WHO performance status 0, 1.
  • 6. Platelets >100 x 10^9/l; WBC > 3 x 10^9/l; neutrophils > 1.5 x 10^9/l.
  • 7. Serum bilirubin =1.5 ULN.
  • 8. Glomerular filtration rate estimated >50ml/min according to Cockcroft & Gault (or equivalent value following local scale/formula).
  • 9. Able to comply with protocol requirements and deemed fit for surgical resection, chemotherapy and radiotherapy.
  • 10. Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 75
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • 1. Distant metastatic disease.
  • 2. Previous or concurrent malignancy diagnoses, except: i) curatively-treated basal cell carcinoma of skin, ii) carcinoma in situ of cervix, iii) previous cancers treated with curative intent, ending treatment = 5 years ago.
  • 3. Serious medical or psychological condition precluding neoadjuvant treatment and surgical resection.
  • 4. Previous chemotherapy ending < 5 years ago (exceptions may be given case by case by the CI, such as methotrexate for rheumatoid arthritis).
  • 5. Pregnancy.
  • 6. WHO performance status 2-4.
  • 7. New York Heart Association Classification Grade III or IV.
  • 8. Uncontrolled angina/ischaemic heart disease.
  • 9. Patients with known malabsorption.

研究者

发起方
niversity of Liverpool

相似试验